Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 15 Immunology (therapy) PhD Projects, Programmes & Scholarships

Discipline

Discipline

Biological Sciences

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


Immunology (therapy) PhD Projects, Programmes & Scholarships

We have 15 Immunology (therapy) PhD Projects, Programmes & Scholarships

NIHR Leeds BRC: Utilising genetic and genomic predictors of vasculitis and disease/treatment complications for application in routine clinical practice

There is substantial interest in using genetic biomarkers to predict those most at risk of disease and treatment complications; this is one of the focuses of Our Future Health, a national study aiming to recruit 5M participants ( https://ourfuturehealth.org.uk/ ). Read more

Immunotherapy: Killing Cancer using Dead Virus

It is now accepted that our immune systems can hold the key to treating otherwise incurable cancers. So-called “immunotherapy” is an increasingly common method of treating tumours, leading to impressive increases in patient responses. . Read more

Design, synthesis and evaluation of protease-activated anti-cancer prodrugs

  Research Group: Institute of Cancer Therapeutics
Matrix metalloproteinases (MMPs) are a family of endoproteases that are overexpressed in tumours and play crucial roles in many tumourigenic processes, not least tumour invasion and angiogenesis. Read more

The epigenomic, transcriptional and diagnostic architecture of neurodevelopmental disorders caused by exposure to maternal infection

A fundamental unknown in understanding mechanisms of disease, and therefore improving therapy, is how stressors experienced during critical developmental periods influence the genesis or ‘programming’ of adult disease (Estes & McAllister 2016). Read more

Cancer: Understanding the immunosuppressive role of fibroblast and macrophages in Breast cancer

Oncolytic viruses (OVs) preferentially infect and kill cancer cells, and their clinical efficacy has been demonstrated against a number of different cancers. The most clinically advanced OV is a genetically engineered herpes simplex virus (T-VEC) which expresses GMCSF to aid the development of anti-tumour immune responses; T-VEC is approved for the treatment of metastatic melanoma. Read more
  • 1

Filtering Results